The purpose of this preference study was to better understand which treatment attributes were most important in selecting novel oral or intravenous treatments among EGFR‐mutant NSCLC patients and treating physicians in Japan using a DCE. This evidence concerns the gene EGFR and non-small cell lung carcinoma.